Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Diversifying Beyond Myeloma Backbone Revlimid

This article was originally published in Scrip

Executive Summary

Celgene Corp.'s product sales increased 21% and earnings grew 27% in 2015, as expected based on guidance given earlier in January, but the company is poised for revenue gains beyond its multiple myeloma backbone therapy Revlimid (lenalidomide) as new product sales growth continues.

Advertisement

Related Content

New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie

Topics

Advertisement
UsernamePublicRestriction

Register

SC064332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel